Diagnostics Xagena

DiagnosticsNews Map
Xagena Newsletter

Gadolinium-based contrast agents for magnetic resonance imaging: FDA is evaluating the risk of brain deposits with repeated use

The FDA ( Food and Drug Administration ) is investigating the risk of brain deposits following repeated use of Gadolinium-based contrast agents ( GBCAs ) for magnetic resonance imaging ( MRI ).
Recent publications in the medical literature have reported that deposits of GBCAs remain in the brains of some patients who undergo four or more contrast MRI scans, long after the last administration.
It is unknown whether these Gadolinium deposits are harmful or can lead to adverse health effects.

FDA, including its National Center for Toxicological Research ( NCTR ), will study this possible safety risk further. FDA is working with the research community and industry to understand the mechanism of Gadolinium retention and to determine if there are any potential adverse health effects. Based on the need for additional information, at this time, FDA is not requiring manufacturers to make changes to the labels of GBCA products.

After being administered, Gadolinium-based contrast agents are mostly eliminated from the body through the kidneys. However, trace amounts of Gadolinium may stay in the body long-term.
Recent studies conducted in people and animals have confirmed that Gadolinium can remain in the brain, even in individuals with normal kidney function.
Available information does not identify any adverse health effects.


To reduce the potential for Gadolinium accumulation, health care professionals should consider limiting GBCA use to clinical circumstances in which the additional information provided by the contrast is necessary.
Health care professionals are also urged to reassess the necessity of repetitive GBCA MRIs in established treatment protocols.

Patients, parents, and caregivers should talk to their health care professionals if they have any questions about the use of Gadolinium-based contrast agents with MRIs.

This issue affects only Gadolinium-based contrast agents; it does not apply to other types of scanning agents used for other imaging procedures, such as those that are Iodine-based or radioisotopes. ( Xagena )

Source: FDA, 2015